CALIBERCOS INC-CL A (CWD) Fundamental Analysis & Valuation

NASDAQ:CWD • US13000T6047

Current stock price

1.08 USD
+0.05 (+4.85%)
At close:
1.02 USD
-0.06 (-5.56%)
After Hours:

This CWD fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. CWD Profitability Analysis

1.1 Basic Checks

  • CWD had negative earnings in the past year.
  • CWD had a negative operating cash flow in the past year.
  • In the past 5 years CWD reported 4 times negative net income.
  • CWD had negative operating cash flow in 4 of the past 5 years.
CWD Yearly Net Income VS EBIT VS OCF VS FCFCWD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 -10M -20M

1.2 Ratios

  • CWD has a worse Return On Assets (-30.73%) than 91.25% of its industry peers.
  • CWD's Return On Equity of -606.55% is on the low side compared to the rest of the industry. CWD is outperformed by 91.67% of its industry peers.
Industry RankSector Rank
ROA -30.73%
ROE -606.55%
ROIC N/A
ROA(3y)-7.38%
ROA(5y)-4.97%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CWD Yearly ROA, ROE, ROICCWD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -200 -400

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for CWD so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CWD Yearly Profit, Operating, Gross MarginsCWD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 60

2

2. CWD Health Analysis

2.1 Basic Checks

  • There is no outstanding debt for CWD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CWD Yearly Shares OutstandingCWD Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
CWD Yearly Total Debt VS Total AssetsCWD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

  • CWD has an Altman-Z score of -1.19. This is a bad value and indicates that CWD is not financially healthy and even has some risk of bankruptcy.
  • CWD has a Altman-Z score of -1.19. This is amonst the worse of the industry: CWD underperforms 87.50% of its industry peers.
  • A Debt/Equity ratio of 13.94 is on the high side and indicates that CWD has dependencies on debt financing.
  • CWD's Debt to Equity ratio of 13.94 is on the low side compared to the rest of the industry. CWD is outperformed by 91.25% of its industry peers.
Industry RankSector Rank
Debt/Equity 13.94
Debt/FCF N/A
Altman-Z -1.19
ROIC/WACCN/A
WACCN/A
CWD Yearly LT Debt VS Equity VS FCFCWD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 50M 100M 150M

2.3 Liquidity

  • A Current Ratio of 1.47 indicates that CWD should not have too much problems paying its short term obligations.
  • CWD has a Current ratio of 1.47. This is in the better half of the industry: CWD outperforms 68.75% of its industry peers.
  • CWD has a Quick Ratio of 1.47. This is a normal value and indicates that CWD is financially healthy and should not expect problems in meeting its short term obligations.
  • CWD's Quick ratio of 1.47 is fine compared to the rest of the industry. CWD outperforms 69.17% of its industry peers.
Industry RankSector Rank
Current Ratio 1.47
Quick Ratio 1.47
CWD Yearly Current Assets VS Current LiabilitesCWD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M 150M

4

3. CWD Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 40.94% over the past year.
EPS 1Y (TTM)40.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%87.84%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-52.46%

3.2 Future

  • CWD is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 42.83% yearly.
  • The Revenue is expected to grow by 22.92% on average over the next years. This is a very strong growth
EPS Next Y95.34%
EPS Next 2Y42.83%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year26.79%
Revenue Next 2Y22.92%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

CWD Yearly Revenue VS EstimatesCWD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 20M 40M 60M 80M
CWD Yearly EPS VS EstimatesCWD Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 0 -5 -10 -15

1

4. CWD Valuation Analysis

4.1 Price/Earnings Ratio

  • CWD reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year CWD is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CWD Price Earnings VS Forward Price EarningsCWD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CWD Per share dataCWD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10

4.3 Compensation for Growth

  • CWD's earnings are expected to grow with 42.83% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y42.83%
EPS Next 3YN/A

0

5. CWD Dividend Analysis

5.1 Amount

  • No dividends for CWD!.
Industry RankSector Rank
Dividend Yield 0%

CWD Fundamentals: All Metrics, Ratios and Statistics

CALIBERCOS INC-CL A

NASDAQ:CWD (4/24/2026, 8:00:01 PM)

After market: 1.02 -0.06 (-5.56%)

1.08

+0.05 (+4.85%)

Chartmill FA Rating
GICS SectorFinancials
GICS IndustryGroupFinancial Services
GICS IndustryCapital Markets
Earnings (Last)03-25
Earnings (Next)05-13
Inst Owners2.3%
Inst Owner Change0%
Ins Owners4.52%
Ins Owner Change0%
Market Cap7.61M
Revenue(TTM)N/A
Net Income(TTM)-25.37M
Analysts80
Price Target7.14 (561.11%)
Short Float %1.35%
Short Ratio1.24
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-333.6%
Min EPS beat(2)-337.12%
Max EPS beat(2)-330.07%
EPS beat(4)0
Avg EPS beat(4)-670.63%
Min EPS beat(4)-1162.38%
Max EPS beat(4)-330.07%
EPS beat(8)2
Avg EPS beat(8)-428.51%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-17.48%
Min Revenue beat(2)-19.63%
Max Revenue beat(2)-15.34%
Revenue beat(4)2
Avg Revenue beat(4)-0.82%
Min Revenue beat(4)-19.63%
Max Revenue beat(4)28.56%
Revenue beat(8)6
Avg Revenue beat(8)88.02%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.31
P/FCF N/A
P/OCF N/A
P/B 1.82
P/tB 1.82
EV/EBITDA N/A
EPS(TTM)-10.63
EYN/A
EPS(NY)-0.49
Fwd EYN/A
FCF(TTM)-0.96
FCFYN/A
OCF(TTM)-0.96
OCFYN/A
SpS3.5
BVpS0.59
TBVpS0.59
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -30.73%
ROE -606.55%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-7.38%
ROA(5y)-4.97%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0.3
Health
Industry RankSector Rank
Debt/Equity 13.94
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.47
Quick Ratio 1.47
Altman-Z -1.19
F-Score1
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)40.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%87.84%
EPS Next Y95.34%
EPS Next 2Y42.83%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-52.46%
Revenue Next Year26.79%
Revenue Next 2Y22.92%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y20.6%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year96.55%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y54.11%
FCF growth 3YN/A
FCF growth 5Y-35.8%
OCF growth 1Y54.11%
OCF growth 3YN/A
OCF growth 5Y-35.8%

CALIBERCOS INC-CL A / CWD Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for CALIBERCOS INC-CL A?

ChartMill assigns a fundamental rating of 2 / 10 to CWD.


Can you provide the valuation status for CALIBERCOS INC-CL A?

ChartMill assigns a valuation rating of 1 / 10 to CALIBERCOS INC-CL A (CWD). This can be considered as Overvalued.


Can you provide the profitability details for CALIBERCOS INC-CL A?

CALIBERCOS INC-CL A (CWD) has a profitability rating of 0 / 10.


How financially healthy is CALIBERCOS INC-CL A?

The financial health rating of CALIBERCOS INC-CL A (CWD) is 2 / 10.